Biotech
FDA Approves Hernexeos for Advanced Lung Cancer with High Tumor Response Rates
The FDA has granted approval to Hernexeos, a breakthrough targeted therapy for advanced lung cancer, marking a significant milestone in oncology treatment options for patients